IMV Inc. (IMV): Price and Financial Metrics


IMV Inc. (IMV): $0.93

0.01 (+1.05%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IMV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IMV POWR Grades


  • IMV scores best on the Sentiment dimension, with a Sentiment rank ahead of 73.95% of US stocks.
  • The strongest trend for IMV is in Growth, which has been heading down over the past 78 days.
  • IMV ranks lowest in Momentum; there it ranks in the 4th percentile.

IMV Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for IMV is 0.01 -- better than merely 6.85% of US stocks.
  • With a price/sales ratio of 799.98, IMV Inc has a higher such ratio than 99.46% of stocks in our set.
  • As for revenue growth, note that IMV's revenue has grown -39.49% over the past 12 months; that beats the revenue growth of only 4.37% of US companies in our set.
  • Stocks that are quantitatively similar to IMV, based on their financial statements, market capitalization, and price volatility, are BNTC, LCTX, APM, SONN, and ZSAN.
  • Visit IMV's SEC page to see the company's official filings. To visit the company's web site, go to imv-inc.com.

IMV Price Target

For more insight on analysts targets of IMV, see our IMV price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.75 Average Broker Recommendation 1.75 (Moderate Buy)

IMV Stock Price Chart Interactive Chart >

Price chart for IMV

IMV Price/Volume Stats

Current price $0.93 52-week high $2.50
Prev. close $0.92 52-week low $0.90
Day low $0.90 Volume 70,400
Day high $1.03 Avg. volume 112,039
50-day MA $1.23 Dividend yield N/A
200-day MA $1.40 Market Cap 76.51M

IMV Inc. (IMV) Company Bio


IMV Inc. operates as a clinical-stage biopharmaceutical company. It is developing cancer immunotherapies and vaccines against infectious diseases, including COVID-19. The company's delivery platform (DPX) programs immune cells directly within the human body to produce robust, specific, and sustained target killing capabilities. Its lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple Phase 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma). DPX-Survivac is evaluated in multiple Phase 2 clinical trials across six cancer indications and also in combination with Merck's Keytruda in two clinical trials. The company is also advancing the development of a DPX-based vaccine candidate against COVID-19 in collaboration with infectious disease experts. In addition, it is developing DPX-RSV, a DPX-based vaccine candidate targeting the respiratory syncytial virus strain A. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.


IMV Latest News Stream


Event/Time News Detail
Loading, please wait...

IMV Latest Social Stream


Loading social stream, please wait...

View Full IMV Social Stream

Latest IMV News From Around the Web

Below are the latest news stories about IMV Inc that investors may wish to consider to help them evaluate IMV as an investment opportunity.

IMV Doses First Patient in the Mid-Stage Study With Keytruda

IMV (IMV) doses first patient in the phase II study evaluating lead compound, maveropepimut-S (MVP-S), in combination with Keytruda

Yahoo | January 13, 2022

IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., January 12, 2022--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced a first patient dosed in the VITALIZE Phase 2B clinical trial. VITALIZE will further evaluate the clinical benefit of IMV’s lead compound, maveropepimut-S (MVP-S), in combination with Merck’s (known as MSD outside the United States and Can

Yahoo | January 12, 2022

IMV Inc. to Present at Two Upcoming Investor Events

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., January 05, 2022--IMV Inc. to Present at Two Upcoming Investor Events

Yahoo | January 5, 2022

Indices - IMV Rating Reiterated by Raymond James

IMV s stock had its market perform rating reiterated by equities researchers at Raymond James in a research report issued to clients and investors on Wednesday, Analyst

Business Mag | December 24, 2021

IMV Names Andrew Hall CEO - Quick Facts

(RTTNews) - IMV Inc. (IMV, IMV.TO) said its Board has appointed Andrew Hall to the role of Chief Executive Office and Director of the Board, effective January 1, 2022. He has more than 20 years of executive experience in biopharmaceuticals and life sciences. In November, 2020, Andrew Hall was appointed to the newly created role of Chief

Business Insider Markets | December 22, 2021

Read More 'IMV' Stories Here

IMV Price Returns

1-mo -23.14%
3-mo -26.77%
6-mo -40.00%
1-year -61.73%
3-year -78.37%
5-year -70.94%
YTD -23.77%
2021 -60.39%
2020 6.21%
2019 -43.91%
2018 -13.60%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7004 seconds.